Mesa Laboratories MLAB Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharmaceutical Development | $48.63M-0.2% | $52.4M+8.5% | $50.26M+10.5% | $48.21M+12.6% | $48.73M+19.7% | |
| Clinical Genomics | $45.39M-3.6% | $44.72M-4.2% | $45.62M-2.1% | $45.97M-9.2% | $47.08M-10.5% | |
| Gross Profit by Business | ||||||
| Biopharmaceutical Development | $28.55M-4.5% | $30.6M+1.1% | $29.22M+2.2% | $28.26M+5.0% | $29.91M+17.8% | |
| Clinical Genomics | $26.03M+1.4% | $24.96M-2.2% | $24.8M-0.9% | $24.61M-8.3% | $25.67M-5.2% | |
| Cost Of Revenue by Business | ||||||
| Biopharmaceutical Development | $20.07M+6.7% | $21.79M+26.2% | $21.04M+28.2% | $19.95M+28.4% | $18.82M+22.9% | |
| Clinical Genomics | $19.36M-9.6% | $19.75M-12.6% | $20.82M-10.5% | $21.37M-11.1% | $21.41M-16.1% | |
| Cost Of Revenue Other by Business | ||||||
| Biopharmaceutical Development | $18.25M+6.0% | $20.01M+27.4% | $19.32M+30.1% | $18.28M+30.9% | $17.22M+25.2% | |
| Clinical Genomics | $18.02M-9.8% | $18.37M-8.9% | $19.55M-0.7% | $19.97M+1.9% | $19.97M-0.8% | |
| Inventory Net by Business | ||||||
| Biopharmaceutical Development | $24.06M— | $22.48M— | —— | —— | —— | |
| Clinical Genomics | $36.18M— | $37.64M— | —— | —— | —— | |
| Cost Of Goods And Services Sold Depreciation by Business | ||||||
| Biopharmaceutical Development | $308K+37.5% | $318K+55.1% | $293K+48.0% | $267K+24.8% | $224K0.0% | |
| Clinical Genomics | $578K-15.0% | $617K-17.5% | $503K-47.8% | $634K-30.7% | $680K-27.4% | |
| Goodwill by Business | ||||||
| Biopharmaceutical Development | $200.43M— | $198.97M— | —— | —— | —— | |
| Clinical Genomics | $68.39M— | $68.2M— | —— | —— | —— | |
| Cost Of Goods And Services Sold Amortization by Business | ||||||
| Biopharmaceutical Development | $1.51M+10.1% | $1.47M+7.8% | $1.43M+5.1% | $1.4M+3.8% | $1.37M+2.6% | |
| Clinical Genomics | $765K0.0% | $765K-54.6% | $765K-70.7% | $765K-78.3% | $765K-82.8% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Clinical Genomics | $196K+1,733% | $193K+330% | $146K— | $126K— | -$12K— | |
| Revenue by Product | ||||||
| Service | $45.74M+7.4% | $44.5M+5.8% | $43.69M+5.6% | $42.7M+5.2% | $42.58M+8.1% | |
| Revenue by Geography | ||||||
| CN | $20.45M-19.2% | $21.43M-19.5% | $22.11M-12.4% | $24.18M-4.7% | $25.31M+1.5% | |
| Other | $111.79M+12.9% | $108.07M+9.7% | $104.53M+9.5% | $100.77M+10.0% | $99.05M+16.7% | |
| US | $116.9M+0.2% | $118.04M+4.8% | $118.62M+10.1% | $117.4M+10.0% | $116.62M+9.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
